Investing.com -- Bioventus Inc. shares climbed as much as 13% on Monday, reaching the highest intraday level since 2024. The increase followed an announcement that the Centers for Medicare & Medicaid Services reversed previously issued reimbursement cuts for the company's non-invasive bone growth stimulators.